GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » Current Ratio

BETRF (BetterLife Pharma) Current Ratio : 0.05 (As of Oct. 2024)


View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BetterLife Pharma's current ratio for the quarter that ended in Oct. 2024 was 0.05.

BetterLife Pharma has a current ratio of 0.05. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If BetterLife Pharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for BetterLife Pharma's Current Ratio or its related term are showing as below:

BETRF' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.16   Max: 16.31
Current: 0.05

During the past 13 years, BetterLife Pharma's highest Current Ratio was 16.31. The lowest was 0.01. And the median was 0.16.

BETRF's Current Ratio is ranked worse than
97.73% of 1495 companies
in the Biotechnology industry
Industry Median: 3.63 vs BETRF: 0.05

BetterLife Pharma Current Ratio Historical Data

The historical data trend for BetterLife Pharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Current Ratio Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.63 0.23 0.28 0.01 0.05

BetterLife Pharma Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.05 0.12 0.07 0.05

Competitive Comparison of BetterLife Pharma's Current Ratio

For the Biotechnology subindustry, BetterLife Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Current Ratio falls into.


;
;

BetterLife Pharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

BetterLife Pharma's Current Ratio for the fiscal year that ended in Jan. 2024 is calculated as

Current Ratio (A: Jan. 2024 )=Total Current Assets (A: Jan. 2024 )/Total Current Liabilities (A: Jan. 2024 )
=0.242/5.086
=0.05

BetterLife Pharma's Current Ratio for the quarter that ended in Oct. 2024 is calculated as

Current Ratio (Q: Oct. 2024 )=Total Current Assets (Q: Oct. 2024 )/Total Current Liabilities (Q: Oct. 2024 )
=0.197/4.268
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BetterLife Pharma  (OTCPK:BETRF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


BetterLife Pharma Current Ratio Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Barbara-jean Anne Bormann-kennedy director, officer: President 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong officer: Chief Financial Officer 2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari director, 10 percent owner 1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian director, officer: Chairman 1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6